Juha-Pekka Erälinna

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS

G. Francis, Richard AC Hughes, John King et al. · DIAL (Catholic University of Leuven) · 2001 · 472 citations

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS

Ludwig Kappos, Anthony Traboulsee, Cris S. Constantinescu et al. · Neurology · 2006 · 255 citations

Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

Per Soelberg Sørensen, Jan Lycke, Juha-Pekka Erälinna et al. · The Lancet Neurology · 2011 · 116 citations

Relapsing-remitting Multiple Sclerosis, Simcombin Study, Immunology +7